Altered chemokine Th1/Th2 balance in addison's disease: Relationship with hydrocortisone dosing and quality of life

Hormone and Metabolic Research

Volumn 46, Issue 1, 2014, Pages 48-53

  Ekman, B ^a   Alstrand, N ^a,b   Bachrach Lindstrom M ^a   Jenmalm, M C ^a   Wahlberg, J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

adrenocortical insufficiency; autoimmunity; chemokines; cortisol

Indexed keywords

CHEMOKINE; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROCORTISONE; MACROPHAGE DERIVED CHEMOKINE; PLACEBO; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADDISON DISEASE; ADULT; AGE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FATIGUE IMPACT SCALE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TH1 TH2 BALANCE;

ADDISON DISEASE; ADULT; ANTHROPOMETRY; CASE-CONTROL STUDIES; CHEMOKINES; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TH1 CELLS; TH2 CELLS;

EID: 84892548557     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0033-1351291     Document Type: Article

References (40)

1. Rotondi M., Falorni A., De Bellis A., Laureti S., Ferruzzi P., Romagnani P., Buonamano A., Lazzeri E., Crescioli C., Mannelli M., Santeusanio F., Bellastella A., Serio M. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab: 2005; 90 2357 2363
2. Lee E. Y., Lee Z. H., Song Y. W. CXCL10 and autoimmune diseases. Autoimmun Rev: 2009; 8 379 383
3. Eizirik D. L., Colli M. L., Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol: 2009; 5 219 226
4. Sandberg M., Frykman A., Ernerudh J., Berg G., Matthiesen L., Ekerfelt C., Nilsson L. J., Jenmalm M. C. Cord blood cytokines and chemokines and development of allergic disease. Pediatr Allergy Immunol: 2009; 20 519 527
5. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol: 2004; 25 677 686
6. Pease J. E., Williams T. J. Chemokines and their receptors in allergic disease. J Allergy Clin Immunol: 2006; 118 305 318; quiz 319-320
7. Betterle C., Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed: 2003; 74 9 33
8. Nerup J., Bendixen G. Anti-adrenal cellular hypersensitivity in Addison's disease. II. Correlation with clinical and serological findings. Clin Exp Immunol: 1969; 5 341 353
9. Freeman M., Weetman A. P. T and B cell reactivity to adrenal antigens in autoimmune Addison's disease. Clin Exp Immunol: 1992; 88 275 279
10. Bratland E., Skinningsrud B., Undlien D. E., Mozes E., Husebye E. S. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab: 2009; 94 5117 5124
11. Doria A., Iaccarino L., Arienti S., Ghirardello A., Zampieri S., Rampudda M. E., Cutolo M., Tincani A., Todesco S. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol: 2006; 22 234 241
12. Wilder R. L. Hormones, pregnancy, and autoimmune diseases. Ann N Y Acad Sci: 1998; 840 45 50
13. Moro M. H., Bjornsson J., Marietta E. V., Hofmeister E. K., Germer J. J., Bruinsma E., David C. S., Persing D. H. Gestational attenuation of Lyme arthritis is mediated by progesterone and IL-4. J Immunol: 2001; 166 7404 7409
14. Elenkov I. J. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci: 2004; 1024 138 146
15. Lovas K., Husebye E. S. Replacement therapy for Addison's disease: recent developments. Expert Opin Investig Drugs: 2008; 17 497 509
16. Groves R. W., Toms G. C., Houghton B. J., Monson J. P. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med: 1988; 81 514 516
17. Howlett T. A. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf): 1997; 46 263 268
18. Lovas K., Husebye E. S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol: 2007; 157 109 112
19. Ekman B., Bachrach-Lindstrom M., Lindstrom T., Wahlberg J., Blomgren J., Arnqvist H. J. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf): 2012; 77 18 25
20. Abrahamsson T. R., Sandberg Abelius M., Forsberg A., Bjorksten B., Jenmalm M. C. A Th1/Th2-associated chemokine imbalance during infancy in children developing eczema, wheeze and sensitization. Clin Exp Allergy: 2011; 41 1729 1739
21. Ware J. E. Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care: 1992; 30 473 483
22. Fisk J. D., Ritvo P. G., Ross L., Haase D. A., Marrie T. J., Schlech W. F. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis: 1994; 18 01 S79 S83
23. Johns M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep: 1991; 14 540 545
24. Bellastella G., Rotondi M., Pane E., Costantini S., Colella C., Calemma R., Capone F., Falorni A., Castello G., Sinisi A. A., Bizzarro A., Chiovato L., Bellastella A., De Bellis A. Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease. J Endocrinol Invest: 2011; 34 831 834
25. Bratland E., Hellesen A., Husebye E. S. Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. Mol Cell Endocrinol: 2013; 365 75 83
26. Antonelli A., Ferrari S. M., Frascerra S., Di Domenicantonio A., Nicolini A., Ferrari P., Ferrannini E., Fallahi P. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab: 2011; 96 1859 1863
27. Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev: 2007; 28 492 520
28. Mah P. M., Jenkins R. C., Rostami-Hodjegan A., Newell-Price J., Doane A., Ibbotson V., Tucker G. T., Ross R. J. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf): 2004; 61 367 375
29. Ten S., New M., Maclaren N. Clinical review 130: Addison's disease 2001. J Clin Endocrinol Metab: 2001; 86 2909 2922
30. Irvine W. J., Stewart A. G., Scarth L. A clinical and immunological study of adrenocortical insufficiency (Addison's disease). Clin Exp Immunol: 1967; 2 31 70
31. Lovas K., Loge J. H., Husebye E. S. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf): 2002; 56 581 588
32. Dantzer R., O'Connor J. C., Freund G. G., Johnson R. W., Kelley K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci: 2008; 9 46 56
33. Ott J., Promberger R., Kober F., Neuhold N., Tea M., Huber J. C., Hermann M. Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid: 2011; 21 161 167
34. Cohen R. A., Albers H. E. Disruption of human circadian and cognitive regulation following a discrete hypothalamic lesion: a case study. Neurology: 1991; 41 726 729
35. Ekman B., Blomgren J., Andersson P. O., Carlsson M., Arnqvist H. J. Variable sensitivity to the glucocorticoid activity of cortisol in patients with primary adrenal insufficiency: assessment with ACTH profiles. Horm Metab Res: 2010; 42 961 966
36. Johannsson G., Nilsson A. G., Bergthorsdottir R., Burman P., Dahlqvist P., Ekman B., Engstrom B. E., Olsson T., Ragnarsson O., Ryberg M., Wahlberg J., Biller B. M., Monson J. P., Stewart P. M., Lennernas H., Skrtic S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab: 2012; 97 473 481
37. Garcia-Borreguero D., Wehr T. A., Larrosa O., Granizo J. J., Hardwick D., Chrousos G. P., Friedman T. C. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J Clin Endocrinol Metab: 2000; 85 4201 4206
38. Taft C., Karlsson J., Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res: 2001; 10 395 404
39. Bleicken B., Hahner S., Loeffler M., Ventz M., Allolio B., Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol: 2008; 159 811 817
40. Verma S., Vanryzin C., Sinaii N., Kim M. S., Nieman L. K., Ravindran S., Calis K. A., Arlt W., Ross R. J., Merke D. P. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 72 441 447